ES2177811T3 - Uso de nitroflavonoides para el tratamiento de la ansiedad. - Google Patents

Uso de nitroflavonoides para el tratamiento de la ansiedad.

Info

Publication number
ES2177811T3
ES2177811T3 ES96935000T ES96935000T ES2177811T3 ES 2177811 T3 ES2177811 T3 ES 2177811T3 ES 96935000 T ES96935000 T ES 96935000T ES 96935000 T ES96935000 T ES 96935000T ES 2177811 T3 ES2177811 T3 ES 2177811T3
Authority
ES
Spain
Prior art keywords
formula
anxiety
nitroflavonoids
treatment
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935000T
Other languages
English (en)
Inventor
Alejandro Constantino Paladini
Jorge Horacio Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Application granted granted Critical
Publication of ES2177811T3 publication Critical patent/ES2177811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

SE DESCRIBEN PROCEDIMIENTOS PARA TRATAR LA ANSIEDAD CON COMPUESTOS FLAVONOIDES SEGUN LA FORMULA (I) Y DIMEROS DE LOS MISMOS, COMPUESTOS DE FORMULA (I) Y DIMEROS DE LOS MISMOS, EL USO DE COMPUESTOS DE FORMULA (I) Y FORMULADOS FARMACEUTICOS QUE INCLUYEN FLAVONOIDES DE FORMULA (I) Y DIMEROS DE LOS MISMOS.
ES96935000T 1995-10-17 1996-10-16 Uso de nitroflavonoides para el tratamiento de la ansiedad. Expired - Lifetime ES2177811T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9521184.3A GB9521184D0 (en) 1995-10-17 1995-10-17 Flavonoids

Publications (1)

Publication Number Publication Date
ES2177811T3 true ES2177811T3 (es) 2002-12-16

Family

ID=10782385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935000T Expired - Lifetime ES2177811T3 (es) 1995-10-17 1996-10-16 Uso de nitroflavonoides para el tratamiento de la ansiedad.

Country Status (9)

Country Link
US (1) US6080780A (es)
EP (1) EP0857066B1 (es)
JP (1) JP4745468B2 (es)
AU (1) AU7310896A (es)
DE (1) DE69621447T2 (es)
ES (1) ES2177811T3 (es)
GB (1) GB9521184D0 (es)
WO (1) WO1997014414A1 (es)
ZA (1) ZA968773B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9707013D0 (en) * 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
US7183314B1 (en) 2000-07-21 2007-02-27 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
RU2209062C1 (ru) * 2002-03-19 2003-07-27 Институт физиологии им. И.П.Павлова РАН Вещество, обладающее седативным действием
GB0216371D0 (en) * 2002-07-13 2002-08-21 Rowett Res Inst The Compounds
US20040033480A1 (en) * 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
EP1957474A4 (en) * 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
EP2117306A4 (en) * 2007-02-14 2010-02-10 Mars Inc NEUROGENIC COMPOUNDS
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
KR20190022085A (ko) * 2017-08-25 2019-03-06 건국대학교 글로컬산학협력단 타마리세틴을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 약학적 조성물
WO2023059802A1 (en) * 2021-10-07 2023-04-13 Rutgers, The State University Of New Jersey Flavonoid derivatives with gabaa receptor activity and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids

Also Published As

Publication number Publication date
US6080780A (en) 2000-06-27
JP2000505055A (ja) 2000-04-25
EP0857066A1 (en) 1998-08-12
DE69621447T2 (de) 2003-05-08
EP0857066B1 (en) 2002-05-29
AU7310896A (en) 1997-05-07
ZA968773B (en) 1997-05-27
DE69621447D1 (de) 2002-07-04
GB9521184D0 (en) 1995-12-20
WO1997014414A1 (en) 1997-04-24
JP4745468B2 (ja) 2011-08-10

Similar Documents

Publication Publication Date Title
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2100151T3 (es) Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2195970T3 (es) L-ribavirina y usos de la misma.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2085876T3 (es) Derivado de bifenilmetano, su utilizacion y composiciones farmacologicas que contienen el mismo.
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
AR020020A1 (es) Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
MX9204522A (es) Derivados 4-benzoil-isoxazol, procedimiento para su preparacion y composicion herbicida que los contiene.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
AR016981A2 (es) Polipeptidos sinteticos
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX9606300A (es) Arilalquiltioalquiltiopiridinas substituidas para combatir bacterias helicobactas.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
AR009809A1 (es) Derivados de 10,13,15-trioxatriciclo[9.2.1(9.6)]-pentadecanona, procedimientos para su preparacion y medicamentos que contienen estos compuestos
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion